JP2005206589A - リパーゼ阻害剤 - Google Patents
リパーゼ阻害剤 Download PDFInfo
- Publication number
- JP2005206589A JP2005206589A JP2004371421A JP2004371421A JP2005206589A JP 2005206589 A JP2005206589 A JP 2005206589A JP 2004371421 A JP2004371421 A JP 2004371421A JP 2004371421 A JP2004371421 A JP 2004371421A JP 2005206589 A JP2005206589 A JP 2005206589A
- Authority
- JP
- Japan
- Prior art keywords
- extract
- lipase inhibitor
- lipase
- lipid
- serum
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 229940086609 Lipase inhibitor Drugs 0.000 title claims abstract description 14
- 208000031226 Hyperlipidaemia Diseases 0.000 claims abstract description 14
- 208000008589 Obesity Diseases 0.000 claims abstract description 13
- 235000020824 obesity Nutrition 0.000 claims abstract description 13
- 239000003795 chemical substances by application Substances 0.000 claims description 9
- 108010021724 tonin Proteins 0.000 claims description 9
- 230000003449 preventive effect Effects 0.000 claims description 5
- 230000000069 prophylactic effect Effects 0.000 claims description 3
- 208000006575 hypertriglyceridemia Diseases 0.000 claims description 2
- 210000002966 serum Anatomy 0.000 abstract description 29
- 150000002632 lipids Chemical group 0.000 abstract description 23
- 239000003814 drug Substances 0.000 abstract description 15
- 229940079593 drug Drugs 0.000 abstract description 13
- 230000002401 inhibitory effect Effects 0.000 abstract description 13
- 102000004882 Lipase Human genes 0.000 abstract description 10
- 108090001060 Lipase Proteins 0.000 abstract description 10
- 239000004367 Lipase Substances 0.000 abstract description 10
- 235000019421 lipase Nutrition 0.000 abstract description 10
- 230000000694 effects Effects 0.000 abstract description 8
- 238000010521 absorption reaction Methods 0.000 abstract description 4
- 241000253121 Inula britannica Species 0.000 abstract description 3
- 240000002924 Platycladus orientalis Species 0.000 abstract description 3
- 210000001035 gastrointestinal tract Anatomy 0.000 abstract description 3
- 241000572565 Alpinia oxyphylla Species 0.000 abstract description 2
- 235000011446 Amygdalus persica Nutrition 0.000 abstract description 2
- 241000559235 Bolboschoenus fluviatilis Species 0.000 abstract description 2
- 241000196324 Embryophyta Species 0.000 abstract description 2
- 102000004190 Enzymes Human genes 0.000 abstract description 2
- 108090000790 Enzymes Proteins 0.000 abstract description 2
- 241001289529 Fallopia multiflora Species 0.000 abstract description 2
- 241001243666 Photinia serratifolia Species 0.000 abstract description 2
- 240000005809 Prunus persica Species 0.000 abstract description 2
- 230000002265 prevention Effects 0.000 abstract description 2
- 238000000354 decomposition reaction Methods 0.000 abstract 2
- 241001643412 Sinomenium Species 0.000 abstract 1
- 238000009825 accumulation Methods 0.000 abstract 1
- 230000003111 delayed effect Effects 0.000 abstract 1
- 230000029226 lipidation Effects 0.000 abstract 1
- 238000002156 mixing Methods 0.000 abstract 1
- 239000000284 extract Substances 0.000 description 27
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 12
- 238000012360 testing method Methods 0.000 description 10
- 229940040461 lipase Drugs 0.000 description 9
- 241000700159 Rattus Species 0.000 description 8
- 230000037396 body weight Effects 0.000 description 7
- 235000005911 diet Nutrition 0.000 description 7
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
- 235000021588 free fatty acids Nutrition 0.000 description 5
- 239000012676 herbal extract Substances 0.000 description 5
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 4
- 102000019280 Pancreatic lipases Human genes 0.000 description 4
- 108050006759 Pancreatic lipases Proteins 0.000 description 4
- 230000000202 analgesic effect Effects 0.000 description 4
- 230000037213 diet Effects 0.000 description 4
- 241000411851 herbal medicine Species 0.000 description 4
- 210000001596 intra-abdominal fat Anatomy 0.000 description 4
- 238000005259 measurement Methods 0.000 description 4
- 239000004006 olive oil Substances 0.000 description 4
- 235000008390 olive oil Nutrition 0.000 description 4
- 229940116369 pancreatic lipase Drugs 0.000 description 4
- 238000012353 t test Methods 0.000 description 4
- 244000144730 Amygdalus persica Species 0.000 description 3
- 206010002091 Anaesthesia Diseases 0.000 description 3
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- 241000220222 Rosaceae Species 0.000 description 3
- 239000004480 active ingredient Substances 0.000 description 3
- 230000037005 anaesthesia Effects 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 238000005119 centrifugation Methods 0.000 description 3
- 230000000378 dietary effect Effects 0.000 description 3
- 239000002934 diuretic Substances 0.000 description 3
- 230000001882 diuretic effect Effects 0.000 description 3
- 230000005764 inhibitory process Effects 0.000 description 3
- 230000000144 pharmacologic effect Effects 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 241000726094 Aristolochia Species 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- 235000006040 Prunus persica var persica Nutrition 0.000 description 2
- 241000208422 Rhododendron Species 0.000 description 2
- 235000004789 Rosa xanthina Nutrition 0.000 description 2
- 238000000692 Student's t-test Methods 0.000 description 2
- 244000223014 Syzygium aromaticum Species 0.000 description 2
- 244000269722 Thea sinensis Species 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 230000000954 anitussive effect Effects 0.000 description 2
- 229940030225 antihemorrhagics Drugs 0.000 description 2
- 229940124584 antitussives Drugs 0.000 description 2
- BBFQZRXNYIEMAW-UHFFFAOYSA-N aristolochic acid I Chemical compound C1=C([N+]([O-])=O)C2=C(C(O)=O)C=C3OCOC3=C2C2=C1C(OC)=CC=C2 BBFQZRXNYIEMAW-UHFFFAOYSA-N 0.000 description 2
- 239000003212 astringent agent Substances 0.000 description 2
- ZZVUWRFHKOJYTH-UHFFFAOYSA-N diphenhydramine Chemical compound C=1C=CC=CC=1C(OCCN(C)C)C1=CC=CC=C1 ZZVUWRFHKOJYTH-UHFFFAOYSA-N 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 235000006694 eating habits Nutrition 0.000 description 2
- 239000002874 hemostatic agent Substances 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 229930014626 natural product Natural products 0.000 description 2
- 238000013116 obese mouse model Methods 0.000 description 2
- 239000003921 oil Substances 0.000 description 2
- 235000019198 oils Nutrition 0.000 description 2
- 210000000496 pancreas Anatomy 0.000 description 2
- WEXRUCMBJFQVBZ-UHFFFAOYSA-N pentobarbital Chemical compound CCCC(C)C1(CC)C(=O)NC(=O)NC1=O WEXRUCMBJFQVBZ-UHFFFAOYSA-N 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 230000001256 tonic effect Effects 0.000 description 2
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 235000019786 weight gain Nutrition 0.000 description 2
- NKQFKJYKCVDLPT-KHPPLWFESA-N (4-methyl-2-oxochromen-7-yl) (z)-octadec-9-enoate Chemical compound CC1=CC(=O)OC2=CC(OC(=O)CCCCCCC\C=C/CCCCCCCC)=CC=C21 NKQFKJYKCVDLPT-KHPPLWFESA-N 0.000 description 1
- LRFVTYWOQMYALW-UHFFFAOYSA-N 9H-xanthine Chemical class O=C1NC(=O)NC2=C1NC=N2 LRFVTYWOQMYALW-UHFFFAOYSA-N 0.000 description 1
- 241000024082 Aristolochia heterophylla Species 0.000 description 1
- 244000223760 Cinnamomum zeylanicum Species 0.000 description 1
- 241000723369 Cocculus trilobus Species 0.000 description 1
- 240000004784 Cymbopogon citratus Species 0.000 description 1
- 235000017897 Cymbopogon citratus Nutrition 0.000 description 1
- 241000234646 Cyperaceae Species 0.000 description 1
- 208000018522 Gastrointestinal disease Diseases 0.000 description 1
- 201000005569 Gout Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 240000004658 Medicago sativa Species 0.000 description 1
- 235000017587 Medicago sativa ssp. sativa Nutrition 0.000 description 1
- 240000007817 Olea europaea Species 0.000 description 1
- 240000008474 Pimenta dioica Species 0.000 description 1
- 235000006990 Pimenta dioica Nutrition 0.000 description 1
- 241000508269 Psidium Species 0.000 description 1
- 208000025747 Rheumatic disease Diseases 0.000 description 1
- 241000220317 Rosa Species 0.000 description 1
- 241000555745 Sciuridae Species 0.000 description 1
- 241001643409 Sinomenium acutum Species 0.000 description 1
- 241001369613 Stephania tetrandra Species 0.000 description 1
- 235000016639 Syzygium aromaticum Nutrition 0.000 description 1
- 244000273928 Zingiber officinale Species 0.000 description 1
- 235000006886 Zingiber officinale Nutrition 0.000 description 1
- 210000000577 adipose tissue Anatomy 0.000 description 1
- 229940024606 amino acid Drugs 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 239000000730 antalgic agent Substances 0.000 description 1
- 230000003266 anti-allergic effect Effects 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000003276 anti-hypertensive effect Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 239000002518 antifoaming agent Substances 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- OGBUMNBNEWYMNJ-UHFFFAOYSA-N batilol Chemical class CCCCCCCCCCCCCCCCCCOCC(O)CO OGBUMNBNEWYMNJ-UHFFFAOYSA-N 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 239000007910 chewable tablet Substances 0.000 description 1
- 235000017803 cinnamon Nutrition 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 239000002826 coolant Substances 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 102000038379 digestive enzymes Human genes 0.000 description 1
- 108091007734 digestive enzymes Proteins 0.000 description 1
- 235000011869 dried fruits Nutrition 0.000 description 1
- 239000002895 emetic Substances 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- -1 etc. are blended Substances 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 239000003172 expectorant agent Substances 0.000 description 1
- 230000003419 expectorant effect Effects 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 235000013376 functional food Nutrition 0.000 description 1
- 235000008397 ginger Nutrition 0.000 description 1
- PQTCMBYFWMFIGM-UHFFFAOYSA-N gold silver Chemical compound [Ag].[Au] PQTCMBYFWMFIGM-UHFFFAOYSA-N 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 230000008991 intestinal motility Effects 0.000 description 1
- 208000017169 kidney disease Diseases 0.000 description 1
- 239000008141 laxative Substances 0.000 description 1
- 230000002475 laxative effect Effects 0.000 description 1
- 235000019626 lipase activity Nutrition 0.000 description 1
- 230000006372 lipid accumulation Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 229940083747 low-ceiling diuretics xanthine derivative Drugs 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 239000012046 mixed solvent Substances 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 235000021590 normal diet Nutrition 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- AHLBNYSZXLDEJQ-FWEHEUNISA-N orlistat Chemical compound CCCCCCCCCCC[C@H](OC(=O)[C@H](CC(C)C)NC=O)C[C@@H]1OC(=O)[C@H]1CCCCCC AHLBNYSZXLDEJQ-FWEHEUNISA-N 0.000 description 1
- 229960001243 orlistat Drugs 0.000 description 1
- 239000003002 pH adjusting agent Substances 0.000 description 1
- 230000036407 pain Effects 0.000 description 1
- 229960001412 pentobarbital Drugs 0.000 description 1
- 235000020737 peppermint extract Nutrition 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000004014 plasticizer Substances 0.000 description 1
- 239000002798 polar solvent Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 230000000552 rheumatic effect Effects 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- 230000000391 smoking effect Effects 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 208000001162 steatorrhea Diseases 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 150000003626 triacylglycerols Chemical class 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 239000002023 wood Substances 0.000 description 1
Images
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
リパーゼは、消化管での脂質の分解を触媒する酵素であり、その働きを阻害すると、脂質の分解が抑制または遅延され、脂質の吸収を抑制することができる。したがって、リパーゼ阻害剤は血清脂質の上昇および体内脂質の蓄積を抑制することから、高脂血症、肥満などの予防あるいは改善に有効である。
本発明の目的は、長期間継続的に服用しても安全かつ効果的な、リパーゼ阻害剤を提供することにある。
【解決手段】
ボウイ、セキナンヨウ、ソクハクヨウ、ヤクチ、カシュウ、チユ、センプクカ、コクサンリョウおよびトウニンからなる群から選ばれる1種または2種以上を配合することを特徴とするリパーゼ阻害剤。
【選択図】 なし
Description
1)ボウイ、セキナンヨウ、ソクハクヨウ、ヤクチ、カシュウ、チユ、センプクカ、コクサンリョウおよびトウニンからなる群から選ばれる1種または2種以上を配合することを特徴とするリパーゼ阻害剤。
2)ボウイ、セキナンヨウ、ソクハクヨウ、ヤクチ、カシュウ、チユ、センプクカ、コクサンリョウおよびトウニンからなる群から選ばれる1種または2種以上を配合することを特徴とする高脂血症の予防または改善剤。
3)高脂血症が高トリグリセライド血症であることを特徴とする2)記載の予防または改善剤。
4)ボウイ、セキナンヨウ、ソクハクヨウ、ヤクチ、カシュウ、チユ、センプクカ、コクサンリョウおよびトウニンからなる群から選ばれる1種または2種以上を配合することを特徴とする肥満の予防または改善剤。
である。
基質溶液(0.2 mM 4-methylumbelliferyl oleate)50μlに実施例1で得た各生薬エキス(2.5% DMSOで溶解)25μLおよび酵素溶液(100U/mL pancreatic lipase,TypeVI-S from porcine pancreas)25μlを添加した。37℃で15分間反応させた後、0.1M塩酸150μLおよび0.1Mクエン酸ナトリウム25μLを加え、励起波長320nm、蛍光波長450 nmにおける蛍光を測定した。なお、各生薬エキスは最終濃度として12.5、25、50および100μg/mLの各濃度で添加した。
18〜20時間絶食したSD系雄性ラット(6〜7週齢、日本チャールスリバー(株))に、実施例1で得た各生薬エキスを300または500mg/kg(乾燥エキス換算)の用量で経口投与し、30分後にオリーブ油を1mL経口投与した。120分後、エーテル麻酔下で後大静脈より採血し、遠心分離(3000rpm、20℃、15分)により、血清を分離した。血清中のトリグリセライド濃度はトリグリセライドE−テストワコー(和光純薬工業(株))を用いて定量した。
結果を表2および図2に示した。
ob/obマウス(6週齢、雄性、日本チャールスリバー(株))に実施例1で得たエキスを300mg/kg(乾燥エキス換算)の用量で1日1回8週間経口投与した。最終投与後、18〜20時間絶食し、エーテル麻酔下で後大静脈から採血し、遠心分離(3000rpm、20℃、15分)により血清を分離した。血清中のトリグリセライド濃度および遊離脂肪酸濃度は、トリグリセライドE−テストワコーおよびNEFAC−テストワコー(いずれも和光純薬工業(株))を用いて定量した。
表および図から明らかなように、セキナンヨウおよびソクハクヨウはob/obマウスの血清脂質の上昇を有意に抑制し、高脂血症、肥満を予防または改善することが明らかになった。
SD系雄性ラット(8週齢、日本チャールスリバー(株))に高カロリー食を摂取させると同時に、実施例1で得たエキスを300mg/kg(乾燥エキス換算)の用量で1日1回8週間経口投与した。なお、正常群には通常食を摂取させた。最終投与後、18〜20時間絶食し、ペントバルビタール麻酔下で後大静脈から採血し、遠心分離(3000rpm、20℃、15分)により血清を分離した。また内臓脂肪を採取し、重量を測定した。血清中のトリグリセライド濃度および遊離脂肪酸濃度は、トリグリセライドE−テストワコーおよびNEFAC−テストワコー(いずれも和光純薬工業(株))を用いて定量した。
Claims (4)
- ボウイ、セキナンヨウ、ソクハクヨウ、ヤクチ、カシュウ、チユ、センプクカ、コクサンリョウおよびトウニンからなる群から選ばれる1種または2種以上を配合することを特徴とするリパーゼ阻害剤。
- ボウイ、セキナンヨウ、ソクハクヨウ、ヤクチ、カシュウ、チユ、センプクカ、コクサンリョウおよびトウニンからなる群から選ばれる1種または2種以上を配合することを特徴とする高脂血症の予防または改善剤。
- 高脂血症が高トリグリセライド血症であることを特徴とする請求項2記載の予防または改善剤。
- ボウイ、セキナンヨウ、ソクハクヨウ、ヤクチ、カシュウ、チユ、センプクカ、コクサンリョウおよびトウニンからなる群から選ばれる1種または2種以上を配合することを特徴とする肥満の予防または改善剤。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2004371421A JP4982946B2 (ja) | 2003-12-26 | 2004-12-22 | リパーゼ阻害剤 |
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2003431789 | 2003-12-26 | ||
JP2003431789 | 2003-12-26 | ||
JP2004371421A JP4982946B2 (ja) | 2003-12-26 | 2004-12-22 | リパーゼ阻害剤 |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2011103356A Division JP5310781B2 (ja) | 2003-12-26 | 2011-05-06 | リパーゼ阻害剤 |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2005206589A true JP2005206589A (ja) | 2005-08-04 |
JP4982946B2 JP4982946B2 (ja) | 2012-07-25 |
Family
ID=34914207
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2004371421A Expired - Fee Related JP4982946B2 (ja) | 2003-12-26 | 2004-12-22 | リパーゼ阻害剤 |
Country Status (1)
Country | Link |
---|---|
JP (1) | JP4982946B2 (ja) |
Cited By (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR101007088B1 (ko) * | 2005-12-30 | 2011-01-10 | (주)아모레퍼시픽 | 생약 및 자생식물 추출물을 함유하는 지방산 산화 촉진용조성물 |
JP2013116889A (ja) * | 2011-10-31 | 2013-06-13 | Kowa Co | 防已含有組成物 |
JP2014214141A (ja) * | 2013-04-30 | 2014-11-17 | 興和株式会社 | 防已含有組成物 |
JP2017515902A (ja) * | 2014-05-12 | 2017-06-15 | 北京慧宝源企▲業▼管理有限公司 | 脂血及び体重を制御する薬物組成物とその応用法 |
WO2018110042A1 (ja) * | 2016-12-14 | 2018-06-21 | 日清食品ホールディングス株式会社 | 脂肪蓄積抑制剤及びこれを含有する飲食品 |
KR20190009461A (ko) * | 2017-07-18 | 2019-01-29 | 한국식품연구원 | 선복화 추출물을 포함하는 비만 또는 운동수행능력 개선용 조성물 |
JP7229772B2 (ja) | 2016-04-22 | 2023-02-28 | ジェイシー(ウーシー) カンパニー,インコーポレーテッド | イソチオシアネート系化合物の使用 |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH0449243A (ja) * | 1990-06-15 | 1992-02-18 | Chiba Seifun Kk | コレステロール低下剤、動物用コレステロール低下剤 |
JPH11269079A (ja) * | 1998-03-17 | 1999-10-05 | Shiseido Co Ltd | 脂質分解促進用皮膚外用剤 |
JP2000060486A (ja) * | 1998-08-27 | 2000-02-29 | Akio Okabe | イボツヅラフジを含有する飲食品 |
-
2004
- 2004-12-22 JP JP2004371421A patent/JP4982946B2/ja not_active Expired - Fee Related
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH0449243A (ja) * | 1990-06-15 | 1992-02-18 | Chiba Seifun Kk | コレステロール低下剤、動物用コレステロール低下剤 |
JPH11269079A (ja) * | 1998-03-17 | 1999-10-05 | Shiseido Co Ltd | 脂質分解促進用皮膚外用剤 |
JP2000060486A (ja) * | 1998-08-27 | 2000-02-29 | Akio Okabe | イボツヅラフジを含有する飲食品 |
Cited By (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR101007088B1 (ko) * | 2005-12-30 | 2011-01-10 | (주)아모레퍼시픽 | 생약 및 자생식물 추출물을 함유하는 지방산 산화 촉진용조성물 |
JP2013116889A (ja) * | 2011-10-31 | 2013-06-13 | Kowa Co | 防已含有組成物 |
JP2014214141A (ja) * | 2013-04-30 | 2014-11-17 | 興和株式会社 | 防已含有組成物 |
JP2017515902A (ja) * | 2014-05-12 | 2017-06-15 | 北京慧宝源企▲業▼管理有限公司 | 脂血及び体重を制御する薬物組成物とその応用法 |
US10548940B2 (en) | 2014-05-12 | 2020-02-04 | Beijing Hebabiz Biotechnology Co., Inc. | Pharmaceutical composition for controlling blood lipids and body weight, and use thereof |
JP7229772B2 (ja) | 2016-04-22 | 2023-02-28 | ジェイシー(ウーシー) カンパニー,インコーポレーテッド | イソチオシアネート系化合物の使用 |
WO2018110042A1 (ja) * | 2016-12-14 | 2018-06-21 | 日清食品ホールディングス株式会社 | 脂肪蓄積抑制剤及びこれを含有する飲食品 |
JP2018095595A (ja) * | 2016-12-14 | 2018-06-21 | 日清食品ホールディングス株式会社 | 脂肪蓄積抑制剤及びこれを含有する飲食品 |
KR20190009461A (ko) * | 2017-07-18 | 2019-01-29 | 한국식품연구원 | 선복화 추출물을 포함하는 비만 또는 운동수행능력 개선용 조성물 |
KR102249795B1 (ko) * | 2017-07-18 | 2021-05-11 | 한국식품연구원 | 선복화 추출물을 포함하는 비만 또는 운동수행능력 개선용 조성물 |
Also Published As
Publication number | Publication date |
---|---|
JP4982946B2 (ja) | 2012-07-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP4929611B2 (ja) | リパーゼ阻害剤 | |
AU2011201268B2 (en) | Antiobesity composition | |
US8741364B2 (en) | Method of improving fat metabolism | |
US7956067B2 (en) | Composition comprising at least one higher aliphatic alcohol and an extract of Griffonia simplicifolia | |
JP2020504153A (ja) | 食欲と欲求を低下させ、満腹感を向上させ、気分を高揚させ、ストレスを低下させるための組成物 | |
KR100883356B1 (ko) | 비만 개선제 조성물 | |
KR20150058234A (ko) | 대사 증후군의 치료를 위한 시나라 스콜리무스, 코페아 속, 및 올레아 유로파에아의 신규한 추출물 | |
US20150141355A1 (en) | Salacia compositions, methods of treatment by their administration, and methods of their preparation | |
JP5609834B2 (ja) | リパーゼ阻害剤 | |
RU2701567C1 (ru) | Средство, обладающее гепатопротекторной активностью | |
JP5310781B2 (ja) | リパーゼ阻害剤 | |
JP4982946B2 (ja) | リパーゼ阻害剤 | |
Al-Snafi et al. | Medicinal Plants with Anti-Obesity Effects: A Special Emphasis on Their Mode of Action. | |
JP4706174B2 (ja) | α−グルコシダーゼ阻害剤 | |
KR101248378B1 (ko) | 관절염 치료 및 예방용 약학조성물 | |
Hashem et al. | Biochemical effects of ginger and/or green tea extracts in high fat diet-induced obese rats. | |
JP4892833B2 (ja) | 脂肪吸収抑制剤 | |
JP4547892B2 (ja) | α−グルコシダーゼ阻害剤 | |
JP6236489B2 (ja) | 逆流性食道炎治療薬 | |
KR20200059268A (ko) | 포만감 및/또는 식욕에 관여하는 펩티드 수준의 조절을 통한 체중 조절용 조성물 | |
Nasution et al. | Correlation between Low-Density Lipoprotein Cholesterol and Certain Lipid Profiles in The Treatment of Bay Leaf Extract (Syzgium Polyanthum (Wight) Walp) to Dyslipidemia Patients | |
JP5706142B2 (ja) | フユボダイジュ花のエタノール抽出物を有効成分とする血中グルコース低下剤、内臓脂肪蓄積抑制剤、tg低下剤、糞中脂肪排泄促進剤 | |
JP4604506B2 (ja) | α−グルコシダーゼ阻害剤 | |
KR100773246B1 (ko) | 연령초 추출물을 유효성분으로 함유하는 비만 억제 및 혈당강하용 조성물 | |
Raina et al. | PTEROCARPUS MARSUPIUM EXTRACT EXAGGERATES ANTI DIABETIC ACTIVITY OF METFORMIN |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20071130 |
|
RD07 | Notification of extinguishment of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7427 Effective date: 20090605 |
|
RD07 | Notification of extinguishment of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7427 Effective date: 20090624 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20110308 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20110506 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20111122 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20120203 |
|
A911 | Transfer to examiner for re-examination before appeal (zenchi) |
Free format text: JAPANESE INTERMEDIATE CODE: A911 Effective date: 20120227 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20120327 |
|
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20120409 |
|
R150 | Certificate of patent or registration of utility model |
Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20150511 Year of fee payment: 3 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20150511 Year of fee payment: 3 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
LAPS | Cancellation because of no payment of annual fees |